Reify Health Public-Source Startup Diligence Report
Reify Health / OneStudyTeam appears to address a large clinical-trial enrollment and operations bottleneck with evidence of global sponsor and site adoption. Investment attractiveness depends on proving durable sponsor-paid revenue, active site network quality, retention, unit economics, competitive differentiation against broad clinical platforms, and compliant handling of sensitive clinical-trial data.
Reify Health Public-Source Startup Diligence Report
Track with high-priority private diligence. Public evidence supports an active late-stage private healthcare/life-sciences unicorn with substantial financing, a sponsor/site clinical-trial operations product, recognizable pharma logos and global site reach. The highest-value diligence remains private: financials, cap table, customer concentration, security/privacy proof, contracts and legal/regulatory searches.
No public audited financials, ARR, gross margin, burn, runway or cash data support underwriting.
Diligence request: Open monthly financial statements, ARR bridge, cash/burn/runway, QoE and bank/debt schedules.
Late-stage financing at high valuation could include preferences, ratchets or investor rights not visible publicly.
Diligence request: Request fully diluted cap table, financing documents, side letters, debt, warrants and waterfall.
Named pharma logos do not reveal revenue concentration, renewals, churn, committed backlog or economics.
Diligence request: Request top-customer revenue, contracts, cohort retention and customer calls.
Large competitors cover adjacent clinical-operations workflows and may pressure pricing or bundle against Reify.
Diligence request: Run win/loss, pricing and switching-cost diligence against named competitors.
Sensitive patient, site and sponsor workflows heighten privacy, security, incident and cross-border compliance exposure.
Diligence request: Request SOC reports, penetration tests, incident logs, DPAs, subprocessors and data maps.
Site counts and product labels vary by source and over time, complicating growth interpretation.
Diligence request: Request a reconciled operating metrics definitions memo and KPI history.
Privacy policy discloses AI-assisted analysis, matching, recommendations and workflow insights; governance controls are not public.
Diligence request: Request AI model governance, human-review controls, DPIAs and customer terms.
Revenue likely depends on pharma/CRO trial-start budgets and site adoption cycles.
Diligence request: Review pipeline conversion, committed bookings, cancellation clauses and sponsor budget sensitivity.
Public evidence supports late-stage financing and valuation signals, but operating financials, forecasts, cash runway, debt and cap-table terms are private and high priority.
partially verified confidence: medium
Public sources provide evidence for Annual and quarterly financial information for the past three years, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Revenue/ARR | No public ARR or revenue found. | ARR bridge, revenue by product/customer, bookings and backlog. | Public absence |
| Gross margin/unit economics | No public margins or cost-to-serve. | COGS, hosting, support and services margin by segment. | Public absence |
| Cash/burn/runway | Funding amounts public; current cash not public. | Cash, burn, runway, debt covenants and board plan. | Public absence |
| Audit/tax/working capital | No public audit/tax schedules. | Audited statements, QoE, taxes, AR/AP and deferred revenue. | Public absence |
not publicly verifiable confidence: low
No sufficient public disclosure was found for Financial Projections; treat this as a data-room request rather than a negative finding.
partially verified confidence: medium
Public sources provide evidence for Capital Structure, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Series A | Sierra says it led a $7.5M Series A in Dec. 2018. | Original financing documents and share class terms. | Investor source |
| Series B | Reify raised $30M in Aug. 2020. | Use of proceeds and security terms. | Business Wire |
| Series C | Reify raised $220M at $2.2B valuation in Aug. 2021. | Cap table and valuation terms. | Business Wire |
| Series D | Reify raised $220M at over $4.8B valuation in Apr. 2022. | Liquidation preferences and current valuation bridge. | Business Wire |
| Tracker status | CB Insights lists $4.80B valuation and unicorn date 2021-08-10. | Treat as market-database signal, not source documents. | CB Insights |
partially verified confidence: medium
Public sources provide evidence for Other financial information, but private diligence is required for underwriting-grade verification.
Public pages support an active StudyTeam/OneStudyTeam product suite for sponsors and sites; product metric definitions and entity boundaries need data-room validation.
partially verified confidence: medium
Public sources provide evidence for Description of each product, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| StudyTeam for Sites | Recruitment, referral management, scheduling, visits, financials and patient database. | Active-usage metrics and site economics. | Company product page |
| StudyTeam for Sponsors | Sponsor dashboard, channel data, risk detection and enrollment performance. | Sponsor contracts and renewal proof. | Company product page |
| Care Access adjacency | Reify says OneStudyTeam and Care Access continue within Reify; referral links are referenced. | Entity boundary and intercompany contracts. | Company pages |
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Site count | 1,800 in 2020; ~4,000 in 2021/Sierra; 7,000 on about page; 10,000+ current/2024. | Monthly active sites and definition bridge. | Multiple public sources |
| Countries/languages | 26 countries in 2020; 65 in 2021; 100+ countries; 105 countries/languages. | Country revenue/site mix and localization obligations. | Multiple public sources |
| Enrollment performance | Six-week acceleration; 25% fewer zero-enrollers; 23% Lilly patient improvement. | Methodology, cohorts and customer references. | Company/press claims |
Public evidence shows recognizable pharma logos, broad sponsor/site reach and site-count growth; revenue concentration, retention and customer contracts are not public.
partially verified confidence: medium
Public sources provide evidence for Top customers by application, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| 2020 traction | 1,800 sites in 26 countries; half of top-20 biopharma. | Contract/revenue proof and active-customer status. | Business Wire |
| 2021 traction | Top-20 biopharma incl. Amgen, AstraZeneca, Eli Lilly; ~4,000 sites in 65 countries. | Renewal terms and cohort retention. | Business Wire |
| Current/2024 scale | 70% of sponsors with most clinical trials; 10,000+ sites; 100+ countries. | Revenue concentration and signed references. | Company/Business Wire |
not publicly verifiable confidence: low
No sufficient public disclosure was found for Strategic relationships; treat this as a data-room request rather than a negative finding.
partially verified confidence: medium
Public sources provide evidence for Revenue by customer, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Top customers by revenue | Not public. | Top 20 customers by ARR/bookings and contract term. | Public absence |
| Retention and churn | Not public. | GRR/NRR, churn reasons and expansion cohorts. | Public absence |
| Severed relationships | Not public. | Lost/de-scoped customers and dispute log. | Public absence |
| Suppliers/cloud dependencies | Privacy policy mentions cloud infrastructure, but vendors are not fully public. | Subprocessor list, cloud contracts and SLAs. | Privacy policy |
not publicly verifiable confidence: low
No sufficient public disclosure was found for Significant relationships severed within the last two years; treat this as a data-room request rather than a negative finding.
not publicly verifiable confidence: low
No sufficient public disclosure was found for Top suppliers; treat this as a data-room request rather than a negative finding.
Reify addresses a large clinical-trial operations problem, but Veeva, Florence and Advarra expose meaningful adjacent platform competition.
partially verified confidence: medium
Public sources provide evidence for Competitive landscape by market segment, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Reify / OneStudyTeam | Enrollment, site workflows, sponsor dashboards, referrals and scheduling. | Differentiated ROI and network effects. | Target company |
| Veeva | Broad clinical operations and Site Connect / CTMS-adjacent workflows. | Suite bundling risk. | Competitor page |
| Florence | Site Enablement Platform for sponsors, CROs and sites. | Site-facing workflow competition. | Competitor page |
| Advarra | Study design, startup, collaboration/training, enrollment planning/tracking, CTMS and eSource. | Regulated workflow competition. | Competitor page |
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Network breadth creates moat | 10K+ sites and 70% sponsor claim. | Site activity, exclusivity and sponsor references. | Company claim |
| Workflow ROI is measurable | Six-week acceleration and fewer zero-enrollers. | Audited ROI cohorts and customer validation. | Product page |
| Large market problem remains | 80% of trials miss recruitment timing; sponsors spend >$70B annually. | TAM/SAM/SOM and budget sensitivity. | Release/investor context |
The public GTM motion appears sponsor-paid and site-adopted, supported by product pages, ROI claims and resources; sales productivity and CAC are private.
partially verified confidence: medium
Public sources provide evidence for Strategy and implementation, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Enterprise sponsor direct sales | Sponsor product pages and major pharma logos. | Pipeline, sales-cycle and ASP by segment. | Company pages |
| Site network adoption | Sites free / sponsors paid model noted by Sierra. | Active site usage, support cost and conversion influence. | Investor source |
| Content and webinars | Datasheets/webinars across modules and use cases. | Campaign attribution and CAC payback. | Resources page |
not publicly verifiable confidence: low
No sufficient public disclosure was found for Major Customers; treat this as a data-room request rather than a negative finding.
not publicly verifiable confidence: low
No sufficient public disclosure was found for Principal avenues for generating new business; treat this as a data-room request rather than a negative finding.
partially verified confidence: medium
Public sources provide evidence for Sales force productivity model, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Enrollment acceleration | Six weeks faster per trial. | Win-rate uplift and validated customer ROI. | Product/release claim |
| Site uptake | 93% site uptake claim. | Deployment cycle, active usage and support burden. | Product page |
| Sales staffing | Careers page lists Sales team. | Rep count, quota, attainment and pipeline coverage. | Careers page |
not publicly verifiable confidence: low
No sufficient public disclosure was found for Ability to implement marketing plan with current and projected budgets; treat this as a data-room request rather than a negative finding.
Public R&D signals include engineering, applied ML/analytics, privacy/security controls, diversity reporting, AI disclosures and workflow modules; roadmap economics remain private.
partially verified confidence: medium
Public sources provide evidence for Description of R&D organization, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Engineering | Careers page features Engineering. | R&D headcount by function/location and roadmap capacity. | Careers page |
| Applied ML & Analytics | Careers page features Applied Machine Learning & Analytics. | Model inventory, governance and staffing. | Careers/privacy |
| Security/privacy engineering | Published TOMs, encryption/retention/incident policies. | SOC reports, pentests, secure SDLC and incident logs. | Privacy/security page |
partially verified confidence: medium
Public sources provide evidence for New Product Pipeline, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Diversity Reporting / BRIDGE | Series D release cites BRIDGE and StudyTeam Diversity Reporting. | Roadmap, adoption and revenue attachment. | Business Wire |
| AI-assisted functionality | Privacy policy discloses AI-assisted analysis, matching, recommendations and workflow insights. | Model governance and customer contract terms. | Privacy policy |
| Visit/referral/slot/calendar modules | Resources and product pages show module expansion. | Module ARR, attach rate and backlog. | Resources/product pages |
Public leadership names and team functions are visible, while current org chart, headcount, compensation, attrition and succession data are not public.
partially verified confidence: medium
Public sources provide evidence for Organization Chart, but private diligence is required for underwriting-grade verification.
Reporting lines are conceptual; verify privately.
partially verified confidence: medium
Public sources provide evidence for Historical and projected headcount by function and location, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Current headcount | Search snippets ranged from 51-200 to 98, 173 and 261 employees. | HRIS export and contractor list. | Search snippets |
| Functional mix | Careers page lists Customer Success, Engineering, Applied ML & Analytics and Sales. | Headcount by function, location, level and product line. | Careers page |
| Compensation/stock/turnover | Benefits are public; compensation, options and attrition are not. | Compensation bands, option plans, attrition and employee relations logs. | Careers/public absence |
partially verified confidence: medium
Public sources provide evidence for Senior management biographies, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Ralph Passarella | CEO in 2022 Series D release; founder per Sierra thesis. | Current role, employment terms and succession. | BusinessWire/Sierra |
| Michael Lin | Executive Chair in 2022 release; founder per Sierra thesis. | Current duties, board rights and equity. | BusinessWire/Sierra |
| Ahmad Namvargolian | Care Access CEO in 2022 release. | Intercompany governance and segment leadership. | BusinessWire |
not publicly verifiable confidence: low
No sufficient public disclosure was found for Compensation arrangements; treat this as a data-room request rather than a negative finding.
not publicly verifiable confidence: low
No sufficient public disclosure was found for Incentive stock plans; treat this as a data-room request rather than a negative finding.
not publicly verifiable confidence: low
No sufficient public disclosure was found for Significant employee relations problems, past or present; treat this as a data-room request rather than a negative finding.
not publicly verifiable confidence: low
No sufficient public disclosure was found for Personnel Turnover; treat this as a data-room request rather than a negative finding.
Trademark, privacy/security and policy disclosures are visible; litigation, insurance, material contracts, regulatory correspondence and IP moat require counsel-led diligence.
partially verified confidence: medium
Public sources provide evidence for Pending lawsuits against the Company, but private diligence is required for underwriting-grade verification.
not publicly verifiable confidence: low
No sufficient public disclosure was found for Pending lawsuits initiated by Company; treat this as a data-room request rather than a negative finding.
not publicly verifiable confidence: low
No sufficient public disclosure was found for Environmental and employee safety issues and liabilities; treat this as a data-room request rather than a negative finding.
partially verified confidence: medium
Public sources provide evidence for Material patents, copyrights, licenses, and trademarks, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Trademark | REIFY HEALTH serial 97341298, class 042 SaaS/services for clinical trials. | Full IP schedule and prosecution status. | Justia/USPTO-derived record |
| Privacy/security controls | Privacy by design, TOMs, encryption, retention, incident response and vendor qualification. | SOC, pentest, incident and DPA artifacts. | Company page |
| AI/data processing | Privacy policy discloses AI-assisted functionality, regional data centers and DPF certification. | DPIAs, subprocessor list and transfer mechanics. | Privacy policy |
not publicly verifiable confidence: low
No sufficient public disclosure was found for Insurance coverage and material exposures; treat this as a data-room request rather than a negative finding.
not publicly verifiable confidence: low
No sufficient public disclosure was found for Material contracts; treat this as a data-room request rather than a negative finding.
partially verified confidence: medium
Public sources provide evidence for Regulatory agency problems, but private diligence is required for underwriting-grade verification.
| topic | public evidence | diligence need | source note |
|---|---|---|---|
| Patents | No obvious Reify Health patent result found in targeted public search. | IP counsel search and assignment review. | Weak public search |
| Litigation | No obvious docket result in targeted search. | Counsel-led litigation and dispute search. | Weak public search |
| Regulatory actions | No obvious FDA warning/regulatory action in targeted search. | Regulatory/privacy counsel review. | Weak public search |
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | CB Insights lists Reify Health as a private unicorn valued at $4.80B, joined 2021-08-10, in Boston, Healthcare & Life Sciences, with Sierra Ventures, Battery Ventures and Asset Management Ventures named as investors. | verified high | SRC-001 |
| EC-002 | Reify Health presents itself as the parent company for OneStudyTeam and Care Access, with Reify branding limited to the parent company. | verified high | SRC-002SRC-008 |
| EC-003 | Public financing releases show Reify raised $30M Series B in 2020, $220M Series C in 2021 at $2.2B valuation, and $220M Series D in 2022 at more than $4.8B valuation. | verified high | SRC-003SRC-004SRC-005 |
| EC-004 | The 2020 Series B release said StudyTeam was used by 1,800 sites in 26 countries and half of top-20 biopharma, with a claimed six-week enrollment acceleration. | verified medium | SRC-003SRC-007 |
| EC-005 | The 2021 Series C release said StudyTeam was used by top-20 biopharma companies including Amgen, AstraZeneca and Eli Lilly and approximately 4,000 research sites across 65 countries. | verified medium | SRC-004 |
| EC-006 | The 2022 Series D release highlighted valuation above $4.8B, BRIDGE, StudyTeam Diversity Reporting and public leadership roles for Ralph Passarella, Michael Lin and Ahmad Namvargolian. | verified high | SRC-005 |
| EC-007 | Sierra Ventures stated it led Reify’s $7.5M Series A in 2018 and that Reify helped close to 4,000 sites, seven of the top ten pharma companies and operations in more than 100 countries, with sites free and sponsors paid. | verified medium | SRC-006 |
| EC-008 | OneStudyTeam claims StudyTeam is trusted by 70% of sponsors with the most clinical trials, spans 100+ countries and more than 10,000 sites, and remains a Reify Health portfolio member. | verified medium | SRC-008 |
| EC-009 | OneStudyTeam’s about page says StudyTeam launched in 2017 with top-20 biopharma and hundreds of sites, but public pages showed a 7,000-site body claim alongside 10,000-site footer/site claims. | partially verified medium | SRC-009SRC-008 |
| EC-010 | StudyTeam for Sites describes recruitment, referral management, direct scheduling, visits, financial workflows and a patient database; public metrics include 500+ trials, 10K+ sites and availability in 105 countries/languages. | verified medium | SRC-010 |
| EC-011 | StudyTeam for Sponsors claims six weeks faster enrollment per trial, 25% fewer zero-enrollers, 93% site uptake, and a Lilly site performance statistic of 23% more patients. | partially verified medium | SRC-011 |
| EC-012 | The 2024 OneStudyTeam release said more than 10,000 research sites use StudyTeam for Sites, available in 15 languages with training in 23 languages, and cited Seacoast Kidney eSource operational improvements. | verified medium | SRC-012 |
| EC-013 | OneStudyTeam publishes privacy/security controls including privacy by design, data minimization, site controller roles, TOMs, data classification, encryption, retention, incident response, vendor qualification and data protection agreements. | partially verified medium | SRC-013 |
| EC-014 | The privacy policy discloses controller/processor roles, AI-assisted functionality, cloud infrastructure sharing, regional data centers, DPF certification and FTC enforcement, while noting safeguards cannot guarantee security. | partially verified medium | SRC-014 |
| EC-015 | OneStudyTeam’s resources library shows a content-led GTM motion with datasheets and webinars across referrals, site workflows, diversity insights, slot management, visit management, calendars and oncology. | verified medium | SRC-015 |
| EC-016 | OneStudyTeam careers pages publicly identify Customer Success, Engineering, Applied Machine Learning & Analytics, and Sales teams, with remote-work and benefits signals. | verified medium | SRC-016 |
| EC-017 | Veeva, Florence and Advarra publicly offer adjacent clinical operations, site collaboration, CTMS, eSource, enrollment and study-startup products, indicating strong platform competition. | verified medium | SRC-017SRC-018SRC-019 |
| EC-018 | Justia/USPTO-derived records show a REIFY HEALTH trademark application, serial 97341298, filed 2022-03-31 in class 042 for SaaS/pro services for clinical trials and clinical-trial data/reporting. | verified high | SRC-020 |
| EC-019 | Targeted public searches found no obvious Reify patent, litigation docket, FDA warning letter or regulatory-action result, but this is weak negative evidence and not a legal search. | inconclusive low | SRC-021 |
| EC-020 | Audited financial statements, ARR, gross margin, burn, runway, debt, cap table, liquidation preferences, customer-level revenue and retention are not public. | not publicly verifiable medium | SRC-001SRC-003SRC-004SRC-005 |
| EC-021 | Public headcount snippets conflict materially, ranging from small-company bands to roughly 98, 173 or 261 employees, so HRIS and payroll data are required. | inconclusive low | SRC-022 |
| EC-022 | Public searches did not identify a current IPO, acquisition or shutdown contradicting private unicorn eligibility, and Reify/OneStudyTeam pages remain active. | inconclusive medium | SRC-001SRC-002SRC-008 |
| EC-023 | Public sources identify Ralph Passarella and Michael Lin as Reify founders/leaders and Ahmad Namvargolian as Care Access CEO in the 2022 financing context. | verified medium | SRC-005SRC-007 |
| EC-024 | Public reports cite the clinical-trials market problem as large and costly, including 80% of trials failing to recruit enough patients on time and sponsors spending more than $70B annually running trials. | verified medium | SRC-003SRC-006 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.